Advertisement
EDIT vs PRTA
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Prothena (PRTA) Stock Comparison
Key Takeaways
- EDIT is a clinical-stage CRISPR gene-editing company rebuilding its pipeline around the in vivo candidate EDIT-401, while PRTA is a late-stage neuroscience and amyloid-focused biotech heavily reliant on partnered programs.
- EDIT has shown stronger year-to-date momentum, whereas PRTA has lagged in 2026 despite a more established clinical portfolio.
- PRTA holds a larger cash balance and a debt-free balance sheet, while EDIT carries higher volatility (beta) and a more concentrated, earlier-stage pipeline.
- Both names carry elevated short interest as a percentage of float, reflecting meaningful investor skepticism around each company's catalysts.
- Risk profiles differ sharply: EDIT hinges on first-in-human gene-editing data, while PRTA depends on milestones and readouts controlled by its large pharmaceutical partners.
Introduction
Investors evaluating clinical-stage biotechnology often weigh two very different models: a high-conviction platform play betting on a single transformative technology versus a diversified, partner-funded pipeline spread across several disease areas. That contrast defines this stock comparison between Editas Medicine (EDIT), a pioneer in CRISPR gene editing, and Prothena Corporation (PRTA), a protein-dysregulation specialist focused on neurodegenerative and amyloid diseases. Both companies are pre-revenue on a product basis, trade at sub-billion-dollar market capitalizations, and carry substantial binary event risk. Growth-oriented traders tracking momentum and relative performance may find EDIT appealing, while investors prioritizing balance-sheet stability and diversified catalysts may favor PRTA.
EDIT Overview and Recent Performance
Editas Medicine (EDIT) develops medicines based on CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology. After discontinuing its reni-cel sickle cell program in late 2024 and reducing its workforce by roughly 65%, the company pivoted to an in vivo strategy centered on EDIT-401, an experimental one-time therapy designed to lower LDL-C (low-density lipoprotein cholesterol) by upregulating the LDL receptor gene in patients with HeFH (heterozygous familial hypercholesterolemia, an inherited cause of high cholesterol).
In recent weeks, EDIT secured regulatory clearance in Australia to begin a first-in-human Phase 1/2 trial of EDIT-401, a milestone that has helped sustain investor interest. Preclinical data reported earlier in 2026 showed mean LDL-C reductions of roughly 90% in non-human primates. The company reported a second-quarter 2026 loss of $0.15 per share on about $11.9 million in collaboration revenue and held approximately $211.6 million in cash as of mid-2026. Shares have outperformed the broader market so far this year, though the stock remains well below its 52-week high and carries a beta above 2, indicating above-average volatility.
PRTA Overview and Recent Performance
Prothena Corporation (PRTA) is a late-stage clinical biotechnology company built around protein dysregulation, targeting conditions such as Parkinson's disease, Alzheimer's disease, ALS (amyotrophic lateral sclerosis), and ATTR-CM (transthyretin amyloidosis with cardiomyopathy). Much of its value rests on partnered assets: prasinezumab with Roche, coramitug with Novo Nordisk, and moponetug and PRX019 with Bristol Myers Squibb.
Recent market activity has been mixed. A $50 million milestone payment from Novo Nordisk drove a profitable first quarter of 2026, but second-quarter revenue fell back sharply as milestone income was non-recurring, and PRTA returned to a net loss. The company ended the second quarter with roughly $289 million in cash and no debt, and management reduced its projected net cash burn for 2026. Despite a stable financial position, the stock has declined on a year-to-date and three-month basis, with sentiment weighed down by the timing of external, partner-controlled catalysts that are not expected to produce pivotal readouts until later this decade.
Trending AI Robots
For investors who prefer a systematic approach to evaluating names like these, Tickeron's Trending AI Robots page offers a curated view of its AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each operating with its own trading style, strategy, timeframe, performance record, and watchlist. Only the most suitable bots for current market conditions earn a place in the Trending AI Robots section, helping traders cut through the noise of a crowded automated-trading landscape. Whether you are monitoring momentum in EDIT or stability in PRTA, reviewing these curated bots can add a data-driven layer to your own analysis.
Head-to-Head Comparison
The two companies occupy different positions within biotechnology. EDIT is a concentrated platform story: its entire near-term thesis depends on EDIT-401 successfully advancing through early clinical testing, which creates high upside potential alongside high single-program risk. PRTA, by contrast, spreads risk across several partnered programs, but cedes much of its catalyst control to Roche, Novo Nordisk, and Bristol Myers Squibb.
On relative performance, EDIT has displayed stronger recent momentum, rising substantially in 2026, while PRTA has trended lower over the same period despite positive one-year performance. On stability, PRTA benefits from a larger cash position, no debt, and lower beta, whereas EDIT faces higher volatility and a tighter runway-to-catalyst profile. Both stocks show comparable elevated short interest as a percentage of float, indicating active debate over their outlooks. Sector exposure is also distinct: EDIT is tied to the emerging gene-editing field, while PRTA sits within the more established antibody and neurodegenerative space.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst proximity, and relative positioning, Tickeron's AI would likely favor EDIT in the current environment. Its stronger recent momentum, combined with a near-term clinical milestone from the Australian trial clearance, aligns more closely with trend-following signals. That said, PRTA presents a more stable balance sheet and a diversified catalyst calendar, which may appeal to models that weight volatility and downside protection more heavily. The verdict is therefore probabilistic rather than definitive: EDIT currently exhibits the more favorable momentum profile, while PRTA offers comparatively greater financial resilience.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and PRTA is a Hold.
Momentum Indicator for EDIT turns negative, indicating new downward trend
EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 77 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 63 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.632) is normal, around the industry mean (2.973). P/E Ratio (-3.773) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PRTA's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for PRTA moved out of oversold territory on September 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRTA advanced for three days, in 201 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRTA as a result. In 81 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PRTA turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PRTA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PRTA crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PRTA entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.476) is normal, around the industry mean (2.973). P/E Ratio (-10.185) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (8.104) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. PRTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EDIT | PRTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 94 | |
PRICE GROWTH RATING 1..100 | 74 | 72 | |
P/E GROWTH RATING 1..100 | 25 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRTA's Valuation (15) in the Biotechnology industry is in the same range as EDIT (42). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.
PRTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.
PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as EDIT (99). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.
PRTA's Price Growth Rating (72) in the Biotechnology industry is in the same range as EDIT (74). This means that PRTA’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's P/E Growth Rating (25) in the Biotechnology industry is in the same range as PRTA (34). This means that EDIT’s stock grew similarly to PRTA’s over the last 12 months.
| EDIT | PRTA | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 74% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 81% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while PRTA’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- PRTA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while PRTA’s TA Score has 3 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 5 bearish.
- PRTA’s TA Score: 3 bullish, 6 bearish.
Price Growth
EDIT (@Biotechnology) experienced а +2.05% price change this week, while PRTA (@Biotechnology) price change was -2.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
EDIT is expected to report earnings on Nov 09, 2026.
PRTA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| CITY.X | 0.298589 | -0.013123 | -4.21% |
| Manchester City Fan Token cryptocurrency | |||
| MKR.X | 1660.356400 | -76.292480 | -4.39% |
| Maker cryptocurrency | |||
| CTK.X | 0.111320 | -0.007085 | -5.98% |
| Shentu cryptocurrency | |||
| RAY.X | 1.834420 | -0.130009 | -6.62% |
| Raydium cryptocurrency | |||
| EDU.X | 0.065980 | -0.006539 | -9.02% |
| Open Campus cryptocurrency | |||